Please upgrade your browser.
ESMO is only 7 days away. Here is an inside look at some of the trials that will be discussed.
Cabozantinib will be the subject of 13 presentations at the European Society for Medical Oncology (ESMO) 2018 Congress, which is being held October 19-23, 2018 in Munich, Germany.
Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma
Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is an uncommon disorder with germline-inactivating mutations in the fumarate hydratase ( FH) gene. The kidney cancers that develop in patients with HLRCC are often unilateral and solitary, with a potentially aggressive clinical course; morphologic identification of suspicious cases is of the utmost importance.
In clinical trials evaluating cancer interventions, there was no significant association between progression-free survival and health-related quality of life, according to research published in JAMA Internal Medicine.
What Makes the Nobel-Winning Breakthroughs in Immunotherapy So Revolutionary Read more: https://www.smithsonianmag.com/science-nature/nobel-winning-breakthroughs-in-immunotherapy-revolutionary-1809704
This week, the 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo for their breakthrough discoveries in immunotherapy. This article by Smithsonian Magazine explains the importance of this approach in treating cancer.
The dismal prognosis for patients with metastatic renal cell carcinoma (mRCC) has fueled an earnest quest for more effective treatments, culminating in a better understanding of the disease and regulatory approval of several new drugs and therapeutic combinations.
The use of robotic tumor enucleation conferred favorable long-term surgical margins and local recurrence rates in patients with sporadic renal cell carcinoma (RCC), according to the results of a single-center Italian study.
Smoking, obesity, hypertension and chronic kidney disease are risk factors for kidney cancer.
We invite you to become a member of PracticeUpdate and the Renal Cell Carcinoma Center of Excellence, an expert-curated resource that’s dedicated to practicing physicians. The Renal Cell Carcinoma Center of Excellence provides physicians with the most up to date information on patient care.
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.
|Powered by NeonCRM|